Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 23-38

  Taliaferro Smith, LaTonia ^a   Nagalingam, Arumugam ^b   Knight, Brandi Brandon ^a,c   Oberlick, Elaine ^a,d   Saxena, Neeraj K ^e   Sharma, Dipali ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; RECOMBINANT LEPTIN; ROSIGLITAZONE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CLONOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84873052595     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121502     Document Type: Article

References (82)

1. Calle EE, Rodriguez C, Walker-Thurmond K, and Thun MJ (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348, 1625-1638.
2. Rose DP, Komninou D, and Stephenson GD (2004). Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5, 153-165.
3. Rose DP, Gilhooly EM, and Nixon DW (2002). Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 21, 1285-1292.
4. Ray A and Cleary MP (2012). Obesity and breast cancer: a clinical biochemistry perspective. Clin Biochem 45, 189-197.
5. Vona-Davis L, Howard-McNatt M, and Rose DP (2007). Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8, 395-408.
6. Vona-Davis L and Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14, 189-206.
7. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC, and Sun CA (2009). Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer 100, 578-582.
8. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, and Surmacz E (2006). Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12, 1447-1453.
9. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, and Chouchane L (2006). Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 6, 38.
10. Irwin ML, McTiernan A, Bernstein L, Gilliland FD, Baumgartner R, Baumgartner K, and Ballard-Barbash R (2005). Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev 14, 2881-2888.
11. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X, and Tian B (2005). Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 26, 19-24.
12. Houseknecht KL, Mantzoros CS, Kuliawat R, Hadro E, Flier JS, and Kahn BB (1996). Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes 45, 1638-1643.
13. Ishikawa M, Kitayama J, and Nagawa H (2004). Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10, 4325-4331.
14. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, and Maihle NJ (2004). Leptin receptor-deficient MMTV-TGF-α/LeprdbLeprdb female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 229, 182-193.
15. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, and Maihle NJ (2003). Genetically obese MMTVTGF-α/LepobLepob female mice do not develop mammary tumors. Breast Cancer Res Treat 77, 205-215.
16. Chua SC Jr, Liu SM, Li Q, Sun A, DeNino WF, Heymsfield SB, and Guo XE (2004). Transgenic complementation of leptin receptor deficiency. II. Increased leptin receptor transgene dose effects on obesity/diabetes and fertility/lactation in lepr-db/db mice. Am J Physiol Endocrinol Metab 286, E384-E392.
17. Park J, Kusminski CM, Chua SC, and Scherer PE (2010). Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am J Pathol 177, 3133-3144.
18. Dogan S, Hu X, Zhang Y, Maihle NJ, Grande JP, and Cleary MP (2007). Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-α mice. Breast Cancer Res 9, R91.
19. Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, and Hursting SD (2008). Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 60, 534-541.
20. Yan D, Avtanski D, Saxena NK, and Sharma D (2012). Leptin-induced epithelialmesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3-and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 287, 8598-8612.
21. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, and Sharma D (2011). Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer 18, 413-428.
22. Kim SH, Nagalingam A, Saxena NK, Singh SV, and Sharma D (2011). Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis 32, 359-367.
23. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, et al. (2010). Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52, 1713-1722.
24. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, and Sharma D (2008). Bidirectional crosstalk between leptin and insulinlike growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 68, 9712-9722.
25. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, and Anania FA (2007). Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67, 2497-2507.
26. Saxena NK, Vertino PM, Anania FA, and Sharma D (2007). Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 282, 13316-13325.
27. Sharma D, Saxena NK, Vertino PM, and Anania FA (2006). Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13, 629-640.
28. Zheng Q, Hursting SD, and Reizes O (2012). Leptin regulates cyclin D1 in luminal epithelial cells of mouse MMTV-Wnt-1 mammary tumors. J Cancer Res Clin Oncol 138, 1607-1612.
29. Guo S, Liu M, Wang G, Torroella-Kouri M, and Gonzalez-Perez RR (2012). Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 1825, 207-222.
30. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SA, et al. (2012). Leptin mediates tumorstromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 72, 1416-1427.
31. Gorden P and Gavrilova O (2003). The clinical uses of leptin. Curr Opin Pharmacol 3, 655-659.
32. Otvos L Jr and Surmacz E (2011). Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev Anticancer Ther 11, 1147-1150.
33. Hu E, Liang P, and Spiegelman BM (1996). AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271, 10697-10703.
34. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, and Matsubara K (1996). cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221, 286-289.
35. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, and Tomita M (1996). Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120, 803-812.
36. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF (1995). A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746-26749.
37. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, and Rewers M (2005). Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111, 747-753.
38. Matsuzawa Y, Funahashi T, Kihara S, and Shimomura I (2004). Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24, 29-33.
39. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, and Pfeiffer AF (2003). Adiponectin and protection against type 2 diabetes mellitus. Lancet 361, 226-228.
40. Goldstein BJ and Scalia R (2004). Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89, 2563-2568.
41. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, and Xu A (2005). Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280, 18341-18347.
42. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769.
43. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, and Lodish HF (2004). T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101, 10308-10313.
44. Kelesidis I, Kelesidis T, and Mantzoros CS (2006). Adiponectin and cancer: a systematic review. Br J Cancer 94, 1221-1225.
45. Hursting SD and Berger NA (2010). Energy balance, host-related factors, and cancer progression. J Clin Oncol 28, 4058-4065.
46. Chen X and Wang Y (2011). Adiponectin and breast cancer. Med Oncol 28, 1288-1295.
47. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, et al. (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89, 1102-1107.
48. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, and Noguchi S (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9, 5699-5704.
49. Arditi JD, Venihaki M, Karalis KP, and Chrousos GP (2007). Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39, 9-13.
50. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, and Pecquery R (2008). Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20, 971-977.
51. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, Cho DH, Lim JS, Kim KI, and Yang Y (2009). Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69, 4018-4026.
52. Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, and Wang Y (2008). Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29, 2195-2202.
53. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, and Xu A (2006). Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66, 11462-11470.
54. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, and Sharma D (2009). LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28, 2621-2633.
55. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, et al. (2007). Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13, 246-252.
56. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, and Yeung SC (2012). Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol [Epub ahead of print 28 September].
57. Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK, and Seewaldt VL (2003). The antiproliferative effects of PPARγ ligands in normal human mammary epithelial cells. Breast Cancer Res Treat 78, 179-192.
58. Patel L, Pass I, Coxon P, Downes CP, Smith SA, and Macphee CH (2001). Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11, 764-768.
59. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, and Yeung SC (2011). The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15, 825-836.
60. Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L, Neumann C, and Reich K (2002). Agonists of peroxisome proliferator-activated receptor γ inhibit cell growth in malignant melanoma. J Invest Dermatol 119, 576-582.
61. Barb D, Pazaitou-Panayiotou K, and Mantzoros CS (2006). Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 15, 917-931.
62. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, and Yuan SS (2006). Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237, 109-114.
63. Steeg PS and Theodorescu D (2008). Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5, 206-219.
64. Ahima RS and Osei SY (2004). Leptin signaling. Physiol Behav 81, 223-241.
65. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, and Flier JS (1998). Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1, 619-625.
66. Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, McGlade CJ, Kennedy BP, and Tremblay ML (2002). Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2, 497-503.
67. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, et al. (2001). PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099.
68. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, and Olefsky JM (2002). The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968-2974.
69. Galli A, Mello T, Ceni E, Surrenti E, and Surrenti C (2006). The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 15, 1039-1049.
70. WhitemanMK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, andMarchbanks PA (2005). Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14, 2009-2014.
71. Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, et al. (2011). Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 47, 1578-1584.
72. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, et al. (2003). Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278, 2461-2468.
73. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE (2001). The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7, 947-953.
74. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, and Lang NP (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25, 1476-1481.
75. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainen JS, Ukkola O, and Morin-Papunen L (2007). Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 156, 263-269.
76. Osei K, Gaillard T, Kaplow J, Bullock M, and Schuster D (2004). Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 53, 1552-1557.
77. Gonzalez-Angulo AM and Meric-Bernstam F (2010). Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16, 1695-1700.
78. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, and Sharma D (2012). Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res 14, R35.
79. Zhu Z, Jiang W, Zacher JH, Neil ES, McGinley JN, and Thompson HJ (2012). Effects of energy restriction and wheel running on mammary carcinogenesis and host systemic factors in a rat model. Cancer Prev Res (Phila) 5, 414-422.
80. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, and Rabson AB (2011). Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32, 1381-1387.
81. Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, et al. (2011). Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 11, 90.
82. Swarbrick MM and Havel PJ (2008). Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6, 87-102.